Intelligent BIO Solutions Inc. INBS

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001725430

E

weakest fifth of 370 graded peers in healthcare

rank 326 of 370; percentile 88.1; sampling error 2.5 points; lower is stronger

A B C D E


E, the bear



Scoreboard


Profitability	D	percentile 64.4
Solvency	D/E	percentile 80.1
Growth and financing	C	percentile 48.6
Reliability	0.76 AUC	filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets	total assets $11.9M
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	dilution, short runway	not computable: distress, fortress balance sheet
Inputs computable	7 of 14	
Graded from	filings received through Oct 21, 2026	8 days before the rescan; latest periodic filing 10-K received Aug 19, 2026
Last close	$1.67	2026-10-28; market equity $5.1M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Aug 19, 2026

context otherwise requires, the terms "we," "us," "our," "Company," or "INBS" refer to Intelligent Bio Solutions Inc. together with its wholly owned subsidiaries. Bio Solutions Inc. and its wholly owned Delaware subsidiary, GBS Operations Inc., were each formed on December 5, 2016, under the laws of the state of Delaware. The Company's Australian subsidiary, Intelligent Bio Solutions (APAC) Pty Ltd, was formed on August 4, 2016, under the laws of New South Wales, Australia. On October 4, 2022, INBS acquired Intelligent Fingerprinting Limited ("IFP"), a company registered in England Bio Solutions Inc.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 64.4						
Gross profitability	17.2%	32.3%		67.7	369	2026-06-30
Return on invested capital	not computable	9.3%				

one or more required annual facts are missing

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(5.0%)	(6.6%)	61.1	805	2026-06-30
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 4					
Solvency, sleeve percentile 80.1					
Twelve-month failure probability	not computable	0.07%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(25.50)	(0.33)	78.0	751	2026-06-30
Net debt to EBITDA	not computable	1.82x			
required facts have no common fiscal period end					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	1.44x	2.94x	82.2	832	2026-06-30
Growth and financing, sleeve percentile 48.6					
Revenue growth, three-year compound	49.7%	10.1%	13.8	413	2026-06-30
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 3					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	4.9%	2.1%	41.5	697	2026-06-30
Net share issuance, one year	237.2%	2.5%	90.3	633	2026-08-18


Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 237.2%
Short runway	cash runway is 4.0 months

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
321	Intellia Therapeutics, Inc. (NTLA)	86.7	E	short runway
322	Heron Therapeutics, Inc. (HRTX)	87.0	E	distress
323	Lexaria Bioscience Corp. (LEXX)	87.3	E	dilution, short runway, distress
324	Bristol Myers Squibb Co. (BMY)	87.7	E	
325	Bristol Myers Squibb Co. (CELG-RI)	87.7	E	
326	Intelligent BIO Solutions Inc. (INBS)	88.1	E	dilution, short runway
327	Maravai Lifesciences Holdings, Inc. (MRVI)	88.3	E	late filer
328	Insight Molecular Diagnostics Inc. (IMDX)	88.6	E	fortress balance sheet
329	Nuwellis, Inc. (NUWE)	88.9	E	dilution, short runway, fortress balance sheet
330	Aclaris Therapeutics, Inc. (ACRS)	89.2	E	short runway, fortress balance sheet
331	Brookdale Senior Living Inc. (BKD)	89.4	E	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-28 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(76.5%)	7.7%	4
Distance from 52-week high	(90.7%)	(27.7%)	4
EBIT to enterprise value	(464.6%)	(1.5%)	2
Free cash flow yield	(238.4%)	(1.0%)	3
Book value to price	1.09	0.27	87
Sales to price	0.83	0.31	79
Composite equity issuance, five years	619.1%	20.5%	98
Relative strength against the sector, log excess return	(1.66)	(0.14)	4

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-06-30	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$4.0M
Operating cash flow, four quarters	-$11.9M
Months of runway	4.0
Days since last periodic filing	71 (10-K received Aug 19, 2026)
Median daily dollar volume, 63 sessions	$72,549

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$2.0M	2026-06-30	2026-08-19	10-K	26-039136
2	assets	us-gaap:Assets	$11.9M	2026-06-30	2026-08-19	10-K	26-039136
3	net income	us-gaap:NetIncomeLoss	-$12.4M	2026-06-30	2026-08-19	10-K	26-039136
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$11.9M	2026-06-30	2026-08-19	10-K	26-039136
5	assets	us-gaap:Assets	$8.2M	2025-06-30	2026-08-19	10-K	26-039136
6	current assets	us-gaap:AssetsCurrent	$7.1M	2026-06-30	2026-08-19	10-K	26-039136
7	current liabilities	us-gaap:LiabilitiesCurrent	$4.9M	2026-06-30	2026-08-19	10-K	26-039136
8	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$75.0M	2026-06-30	2026-08-19	10-K	26-039136
9	operating income	us-gaap:OperatingIncomeLoss	-$12.6M	2026-06-30	2026-08-19	10-K	26-039136
10	book equity	us-gaap:StockholdersEquity	$5.5M	2026-06-30	2026-08-19	10-K	26-039136
11	liabilities	us-gaap:Liabilities	$6.7M	2026-06-30	2026-08-19	10-K	26-039136
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.2M	2026-06-30	2026-08-19	10-K	26-039136
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.1M	2025-06-30	2026-08-19	10-K	26-039136
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.1M	2024-06-30	2025-08-15	10-K	25-024279
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.3M	2023-06-30	2024-09-18	10-K	24-036953
16	assets	us-gaap:Assets	$13.8M	2024-06-30	2025-08-15	10-K	25-024279
17	assets	us-gaap:Assets	$10.4M	2023-06-30	2024-09-18	10-K	24-036953
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	3,027,470	2026-08-18	2026-10-21	10-K/A	26-047925

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,979,152	2025-08-12	2025-08-15	10-K	25-024279	